 | |
 | |
| Company type | Public |
|---|---|
| TYO:4506 | |
| Industry | |
| Predecessors |
|
| Founded | October 1, 2005; 20 years ago (2005-10-01) (merger of Dainippon Pharmaceuticals & Sumitomo Pharmaceuticals) |
| Headquarters | Doshomachi,Chuo-ku,Osaka, Japan |
Key people | Hiroshi Nomura, (president andCEO) |
| Brands | |
| Revenue | $4.18 billion (¥555.54 billion) (FY 2022)[* 1] |
| -$580 million (-¥77.0 billion) (FY 2022)[* 1] | |
| -$728 million (-¥96.7 billion) (FY 2022)[* 1] | |
| Total assets | $8.55 billion (¥1,134.7 billion) (FY 2022)[* 1] |
| Total equity | $3.06 billion (¥406.8 billion) (FY 2022)[* 1] |
Number of employees | 6,250 (consolidated) 3,026 (non-consolidated) (as of March 31, 2023) |
| Website | www |
Footnotes / references
| |
Sumitomo Pharma Company Limited (住友ファーマ株式会社,Sumitomo Fāma Kabushiki-Gaisha) is a Japanese multinationalpharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located inChuo-ku,Osaka.[1]
The original Dainippon Pharmaceuticals (Dainippon Seiyaku) was established in 1885 byNagayo Sensai, a graduate of Tekijuku – the first private medical school in Japan established byOgata Kōan. It was set up as a wholly privately owned company funded by individuals from Tokyo and Osaka, with the government lending it land and buildings. Technical expertise for the enterprise was provided by Shibata Shokei andNagai Nagayoshi.
The company started its operation in the same year with equipment imported from Germany. The main products weretincture and other similar drugs listed in the JapanesePharmacopoeia. Among them wasephedrine, an anti-asthma drug invented by Nagai. In 1893, however, Nagai left the company and the business started to record operating losses. In 1898 it was acquired by Osaka Seiyaku.
The company producedmethamphetamine under the brand name Philopon during WWII for the Imperial Japanese military.[2]
Years later, Sumitomo Pharmaceuticals was incorporated separately in 1984 as a subsidiary ofSumitomo Chemical.[3][needs update] Dainippon and Sumitomo merged on October 1, 2005, to create Dainippon Sumitomo Pharma.[4] As a result, Sumitomo Chemical has maintained a 51%+ ownership in the company since.[5]
Operating without a sales foothold in North America, then-Sumitomo Dainippon Pharma acquired NASDAQ-traded Sepracor for $2.6B in 2009, renaming its new stand-alone subsidiarySunovion in 2010.[6] Under Sunovion management, Sumitomo Dainippon Pharma was able to successfully market its $2B blockbuster drugLatuda in North America, anatypical antipsychotic approved for the treatment ofschizophrenia and depressive episodes associated withBipolar I disorder. In addition to Latuda,Sunovion achieved other notable commercial achievements with marketed drugs such asLunesta,Aptiom, andBrovana.
In September 2016, theSunovion subsidiary announced it would acquireCynapsus Therapeutics for approximately $624 million, to expand Sunovion's central nervous system drug portfolio. With the deal, Sunovion would acquire Cynapsus' then-Phase III Parkinson's disease candidate drugKynmobi,[7] a sublingual formulation ofapomorphine.[8]
Sumitomo Dainippon Pharma announced a $3B upfront acquisition in September 2019 of fiveRoivant subsidiaries, including Urovant and Enzyvant.[9]
On April 1, 2022, the company was renamed from Sumitomo Dainippon Pharma to Sumitomo Pharma.
In October 2022, Sumitomo Pharma announced the acquisition of all outstanding shares in Myovant, a formerRoivant subsidiary it was previously a majority owner of, valuing the company at $2.9B.[10]
Following the Myovant acquisition in April 2023, Sumitomo Pharma consolidated its US subsidiaries to formSumitomo Pharma America, Inc., a wholly owned subsidiary biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient needs spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies.[11]
The following is an illustration of the company's major mergers and acquisitions and historical predecessors:
Members ofHakusuikai arebolded. Hakusuikai is an association of the presidents of the Sumitomo companies. *Mitsui Group companies | ||
| Construction |  | |
| Chemicals and pharmaceuticals | ||
| Rubber, glass and ceramics | ||
| Steel | ||
| Non-ferrous metals | ||
| Machinery | ||
| Electrical equipment | ||
| Trading | ||
| Finance and insurance | ||
| Real estate | ||
| Transport and warehousing | ||
| Information and communication | ||
| International | |
|---|---|
| National | |
